SCHEMBL6737397

SCHEMBL6737397

O=C(c1cnc(-c2ccncc2)nn1)N1C2CN(S(=O)(=O)c3ccc4cc(Cl)ccc4c3)CC1C(O)C2O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
F10 P00742 11/20 0.45
ATM Q13315 1/20 0.39
LMNA P02545 2/20 0.39
CHRM1 P11229 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6733558 0.90 F10 (0.37) F10LMNAHDAC3HDAC4HDAC1
SCHEMBL6730867 0.90 F10 (0.47) F10ATMLMNACHRM1SMN1; SMN2
SCHEMBL6725397 0.87 F10 (0.45) F10ATMLMNACHRM1SMN1; SMN2
SCHEMBL6729053 0.86 F10 (0.44) F10ATMLMNACHRM1SMN1; SMN2
SCHEMBL6734775 0.85 F10 (0.44) F10
SCHEMBL6730950 0.85 F10 (0.41) F10
SCHEMBL6729714 0.85 F10 (0.48) F10ATMLMNACHRM1SMN1; SMN2
SCHEMBL6734441 0.85 F10 (0.47) F10ATMLMNACHRM1SMN1; SMN2
SCHEMBL6728415 0.83 LMNA (0.57) F10ATMLMNASMN1; SMN2GAA
SCHEMBL6731176 0.83 F10 (0.45) F10ATMLMNACHRM1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 F10 19/4885ATM 2080/4885LMNA 1760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.